BioStem Technologies, Inc. — Form S-1
Filed September 18, 2026 · analyzed by the Registration Agent
S-1
▲ Likely positive
significance 72/100
What the filing says
BioStem Technologies filed Form S-1 on September 18, 2026, registering 12,050,000 common shares ($0.001 par) for resale by a selling stockholder under a purchase agreement dated the same day. The filing references an acquisition of BioTissue Surgical and Wound Care product lines, with Grant Thornton providing audit consent for those acquired assets as of June 30, 2026. KPMG audited BioStem's consolidated statements as of April 16, 2026.
Why this rating
Secondary offering of 12M shares is material relative to $48.8M asset base; acquisition adds product lines and revenue diversification. Pending capital raise and M&A are significant, though resale structure limits direct cash impact.
Price action (we called it positive)
before filing · preread $4.74 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.